Regeneron (REGN) Tops Q4 EPS by 109c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron (REGN) jumps on robust Q4 earnings
February 2, 2024 7:32 AM ESTShares of Regeneron Pharmaceuticals (NASDAQ: REGN) jumped more than 5% in pre-market trading Friday after the pharma company posted better-than-anticipated Q4 earnings.
Regeneron reported adjusted earnings per share (EPS) of $11.86 for the fourth quarter, beating the consensus projection of $10.62. Revenue came in at $3.43 billion,... More
